Mecamylamine is a ganglionic nicotinic acetylcholine receptor antagonist that inhibits transmission through autonomic ganglia. It is a synthetic small-molecule pharmaceutical compound that has historically been used as an antihypertensive agent.
Mecamylamine crosses the blood-brain barrier and can inhibit both peripheral and central nicotinic cholinergic signaling. Its pharmacological activity results primarily from blockade of neuronal nicotinic acetylcholine receptors.
Mecamylamine is a synthetic aminocyclohexane derivative with the molecular formula C11H21N and a molecular weight of approximately 167.30 g/mol. Its CAS Number is 60-40-2.
Mecamylamine is commonly handled as a pharmaceutical active ingredient or research compound, with the applicable salt form and specification determined by the intended pharmaceutical application.
Mecamylamine acts as a noncompetitive antagonist of neuronal nicotinic acetylcholine receptors. By blocking nicotinic receptor-mediated transmission in autonomic ganglia, it reduces sympathetic and parasympathetic nerve signaling.
This ganglionic blockade can produce a reduction in peripheral vascular resistance and blood pressure.
Mecamylamine has historically been used as an oral antihypertensive agent for the treatment of hypertension. Because ganglionic blockade affects autonomic nervous system function broadly, its clinical use has become limited compared with newer antihypertensive therapies.
Mecamylamine has also been investigated as a pharmacological tool in research involving nicotinic acetylcholine receptors, nicotine dependence and central nervous system signaling.
Mecamylamine API can be evaluated using validated analytical methods for identification, assay, related substances, water content, residual solvents, elemental impurities and other applicable quality attributes.
Chromatographic and spectroscopic techniques may be used for identity, assay and purity determination. Appropriate controls should be established for process-related impurities, degradation products and residual solvents.
Final acceptance criteria should be based on the applicable manufacturer's approved drug-substance specification and Certificate of Analysis.
Mecamylamine should be stored in a tightly closed pharmaceutical-grade container under controlled conditions and protected from excessive heat, moisture and direct light.
Specific storage and transportation requirements should follow the applicable manufacturer's approved specification.
Mecamylamine API may be supplied for qualified pharmaceutical manufacturing, formulation development, analytical and research applications, subject to applicable quality and regulatory requirements.
Mecamylamine API is available for qualified pharmaceutical development and manufacturing requirements. Customers can request product specifications, Certificate of Analysis, analytical documentation, packaging information and commercial details according to their requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 2.0% |
| Residue on Ignition | NMT 1.0% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 6.0 – 8.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 2.0% |